Amnion derived adherent cells

• US 9,198,938 B2
• Filed: 12/26/2012
• Issued: 12/01/2015
• Est. Priority Date: 11/19/2008
• Status: Active Grant

• Current Assignee: Celularity, Inc.
• Original Assignee: Antrhogenesis Corporation
• Inventors: Abbot, Stewart, Edinger, James W., Francki, Aleksandar, Kaplunovsky, Aleksandr, Jankovic, Vladimir, Labazzo, Kristen, Law, Eric, Padliya, Neerav, Paredes, Jennifer, Wang, Jia-Lun
• Primary Examiner(s): Ton, Thaian N
• Application Number:
  US13/727,217
• Publication Number:
  US 20130315875A1
• Time in Patent Office: 1,070 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly

Abstract

Provided herein are novel angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising, such cells. Further provided herein are methods of obtaining such cells and methods of using the cells in the treatment of individuals.

Claims

1. A method of treating an individual having a disruption of blood flow in or around a limb comprising administering to said individual a population of cells, wherein at least 50% of the cells in said population are human amnion derived adherent cells, wherein said amnion derived adherent cells are adherent to tissue culture plastic, and wherein said amnion derived adherent cells are OCT-4- as determinable by RT-PCR, and CD49f⁺, CD90⁺, and HLA-G- as determinable by flow cytometry, wherein said cells promote angiogenesis and blood flow is improved in or around said limb.

2. The method of claim 1, wherein at least 70%, 80%, 90%, 95%, or 99% of the cells in said population are said amnion derived adherent cells.

3. The method of claim 1, wherein said population of cells 4 is formulated in a hydrogel solution.

4. The method of claim 1, wherein said disruption of blood flow in or around a limb is peripheral arterial disease.

5. The method of claim 1, wherein said disruption of blood flow in or around a limb is critical limb ischemia.

6. The method of claim 1, wherein at least 70% of the cells in said population are said amnion derived adherent cells.

7. The method of claim 1, wherein at least 80% of the cells in said population are said amnion derived adherent cells.

8. The method of claim 1, wherein at least 90% of the cells in said population are said amnion derived adherent cells.

9. The method of claim 1, wherein at least 95% of the cells in said population are said amnion derived adherent cells.

10. The method of claim 1, wherein at least 99% of the cells in said population are said amnion derived adherent cells.

11. The method of claim 4, wherein at least 70% of the cells in said population are said amnion derived adherent cells.

12. The method of claim 4, wherein at least 80% of the cells in said population are said amnion derived adherent cells.

13. The method of claim 4, wherein at least 90% of the cells in said population are said amnion derived adherent cells.

14. The method of claim 4, wherein at least 95% of the cells in said population are said amnion derived adherent cells.

15. The method of claim 4, wherein at least 99% of the cells in said population are said amnion derived adherent cells.

16. The method of claim 5, wherein at least 70% of the cells in said population are said amnion derived adherent cells.

17. The method of claim 5, wherein at least 80% of the cells in said population are said amnion derived adherent cells.

18. The method of claim 5, wherein at least 90% of the cells in said population are said amnion derived adherent cells.

19. The method of claim 5, wherein at least 95% of the cells in said population are said amnion derived adherent cells.

20. The method of claim 5, wherein at least 99% of the cells in said population are said amnion derived adherent cells.